Dalton Bioanalytics

Dalton Bioanalytics has developed and commercialized a mass spectrometry-based "one-shot" multiomics platform called Omni-MS®, capable of simultaneously analyzing proteins, lipids, electrolytes, metabolites, drugs, environmental chemicals and other molecules from a single sample. This enables comprehensive molecular analysis at lower cost with high data integration. The technology supports applications in biomarker discovery, drug development support/clinical research assays for biopharma/biotech companies as well as food/product development. No clinical trial results are reported since the company does not develop its own therapeutics.